FUNDAMENTALS:
GILD (Gilead Sciences) is that company that found the cure for hepatitis C. The fundamentals are improving again. The industry has not done as well as in others. However, with the recent acquisition of MYR Pharmaceuticals (myr-pharma.com), GILD is currently in phase 3 for the treatment of hepatitis B and D.
TECHNICALS:
Monthly:
wedge pattern and volume divergence tells of that institutions and investors may begin to sponsor this company again.
MACD divergence
Weekly:
regular divergence confirms the case for the monthly pattern
breach to new minor highs within a larger pattern
positive MACD development
volume support
Daily:
Crown pattern
Volume confirmation
Daily horizontal support
Daily wedge pattern being tested and broken
GILD (Gilead Sciences) is that company that found the cure for hepatitis C. The fundamentals are improving again. The industry has not done as well as in others. However, with the recent acquisition of MYR Pharmaceuticals (myr-pharma.com), GILD is currently in phase 3 for the treatment of hepatitis B and D.
TECHNICALS:
Monthly:
wedge pattern and volume divergence tells of that institutions and investors may begin to sponsor this company again.
MACD divergence
Weekly:
regular divergence confirms the case for the monthly pattern
breach to new minor highs within a larger pattern
positive MACD development
volume support
Daily:
Crown pattern
Volume confirmation
Daily horizontal support
Daily wedge pattern being tested and broken
Nota
Target: 165
Capturing the swings of the stock market & currency market. It's a dirty job and equity/currency traders must do it.
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.
Capturing the swings of the stock market & currency market. It's a dirty job and equity/currency traders must do it.
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.